Opinion|Videos|July 29, 2024
Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
- Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
- What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5